Barclays
TARA icon

Barclays’s Protara Therapeutics TARA Stock Holding History

Barclays’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71.1K Sell
18,607
-29,655
-61% -$141K ﹤0.01% 4192
2026
Q1 		$251K Sell
48,262
-6,795
-12% -$40.2K ﹤0.01% 3559
2025
Q4 		$293K Buy
55,057
+9,537
+21% +$53K ﹤0.01% 4140
2025
Q3 		$198K Sell
45,520
-10,119
-18% -$32.8K ﹤0.01% 4321
2025
Q2 		$169K Sell
55,639
-37,600
-40% -$130K ﹤0.01% 4377
2025
Q1 		$397K Hold
93,239
– – ﹤0.01% 3664
2024
Q4 		$492K Buy
+93,239
New +$301K ﹤0.01% 3832
2022
Q2 		– Sell
-2,510
Closed -$13K – 5260
2022
Q1 		$13K Buy
+2,510
New +$13.2K ﹤0.01% 4552
2015
Q4 		– Sell
-1
Closed -$1K – 6545
2015
Q3 		$1K Sell
1
-3
-75% -$1.86K ﹤0.01% 6599
2015
Q2 		$2K Buy
+4
New +$2.47K ﹤0.01% 6819

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Barclays's TARA Position: Q2 2026 in Review

Barclays reduced its Protara Therapeutics (TARA) stake by 61% in Q2 2026, selling an estimated $141K and leaving 18,607 shares worth $71.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4192.

Barclays first reported a position in TARA in Q2 2015 and has held it in 10 quarters since. The position peaked at $492K in Q4 2024. 119 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Barclays held 18,607 shares of Protara Therapeutics worth $71.1K as of Q2 2026.
  • Barclays sold 29,655 Protara Therapeutics shares in Q2 2026, an estimated $141K.
  • Protara Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4192 holding.
  • Barclays first reported a position in Protara Therapeutics in Q2 2015 and has held it in 10 quarters since.
  • Barclays's Protara Therapeutics position peaked at $492K in Q4 2024.
  • 119 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.